Vanguard Group Inc. Decreases Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Vanguard Group Inc. decreased its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 5.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,590,974 shares of the company’s stock after selling 292,411 shares during the period. Vanguard Group Inc. owned about 9.69% of Twist Bioscience worth $113,273,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in shares of Twist Bioscience by 11.1% during the 2nd quarter. BlackRock Inc. now owns 6,905,031 shares of the company’s stock valued at $141,277,000 after buying an additional 691,590 shares during the period. State Street Corp boosted its position in Twist Bioscience by 19.2% in the first quarter. State Street Corp now owns 5,275,841 shares of the company’s stock worth $79,560,000 after purchasing an additional 849,592 shares during the last quarter. Capital World Investors grew its stake in shares of Twist Bioscience by 6.0% during the 1st quarter. Capital World Investors now owns 4,795,848 shares of the company’s stock valued at $236,819,000 after purchasing an additional 273,148 shares during the period. JPMorgan Chase & Co. increased its position in shares of Twist Bioscience by 4.2% during the 1st quarter. JPMorgan Chase & Co. now owns 4,057,312 shares of the company’s stock valued at $61,185,000 after purchasing an additional 162,161 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Twist Bioscience by 10.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,258,394 shares of the company’s stock valued at $43,993,000 after purchasing an additional 120,489 shares during the last quarter.

Analyst Ratings Changes

TWST has been the subject of several recent research reports. Barclays boosted their target price on shares of Twist Bioscience from $30.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Scotiabank upped their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th.

Twist Bioscience Price Performance

TWST opened at $33.34 on Thursday. The company has a 50 day simple moving average of $36.46 and a two-hundred day simple moving average of $29.17. The firm has a market cap of $1.93 billion, a P/E ratio of -9.24 and a beta of 1.62. Twist Bioscience Co. has a 1-year low of $11.46 and a 1-year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The company had revenue of $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. During the same quarter in the prior year, the firm posted ($0.74) EPS. Twist Bioscience’s quarterly revenue was up 31.8% compared to the same quarter last year. Equities analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the transaction, the chief executive officer now owns 516,409 shares in the company, valued at $19,329,188.87. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Emily M. Leproust sold 1,128 shares of Twist Bioscience stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total value of $37,810.56. Following the completion of the sale, the chief executive officer now directly owns 515,281 shares in the company, valued at $17,272,219.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,301 shares of company stock worth $294,282. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.